Scientific knowledge of treatments for the coronavirus continues to grow at an unparalleled rate, but there remains more to learn. UC Davis has been integral in the global collaboration to advance effective science-based care for COVID-19 patients and will continue to adapt treatments as research advances.

Remdesivir and convalescent plasma are being used to control viral infection (or replication), and dexamethasone is used to control the immune response to infection. These treatments assist with recovery for those diagnosed with COVID-19. These drugs have often proven more successful than using a ventilator, which sometimes has made lung inflammation worse.

Remdesivir is an antiviral drug. It targets the replication and progression of viral infections such as the novel coronavirus. It is being tested as a treatment for COVID‑19 and has been authorized for emergency use for people with severe symptoms. However, it’s not yet known whether it is a safe and effective treatment. Experimental use at UC Davis Medical Center suggests the drug could have benefits for very ill patients. UC Davis Health is currently conducting two clinical trials with the drug to evaluate its efficacy.

An analysis of seven studies of severely ill COVID-19 patients treated with corticosteroids, including dexamethasone, found the drugs significantly helped reduced deaths from the disease. The World Health Organization now strongly recommends steroids for treatment of patients with severe or critical COVID-19 worldwide, but it recommended against steroid use when the disease is mild. The international clinical trials studied dexamethasone, hydrocortisone and methylprednisolone – inexpensive and widely available steroids commonly used to reduce inflammation and moderate the body’s immune system.

Yes, but perhaps not at the same levels as during the early stages of the pandemic. The National Institutes for Health (NIH) has developed guidelines for adults with COVID-19 who are receiving supplemental oxygen. The NIH recommends close monitoring for worsening respiratory status and the use of a mechanical ventilator, if it becomes necessary. However, experts also say that when COVID-19 patients require mechanical ventilation, there is risk of lung injury due to the ventilation itself. Physicians are being very thoughtful about the use of ventilators because of those concerns. We have changed our treatment methods as more research becomes available and are trying to avoid using ventilators when possible, due to the negative effects they can have on lung inflammation.

Hydroxychloroquine is an arthritis medicine and anti-malaria treatment that also has been tried as a COVID-19 treatment. The Infectious Diseases Society of America revised its COVID-19 treatment guidelines earlier this month, recommending against its use for hospitalized patients with COVID-19. Hydroxychloroquine may have significant side effects, including reports of serious heart rhythm problems and other safety issues, blood and lymph system disorders, kidney injuries, and liver problems and failure.

UC Davis Health is working on effective treatments to increase the survival rate of people with COVID-19. As noted above, we have changed our treatment methods as more research becomes available and are trying to avoid using ventilators when possible, due to the negative effects they can have on lung inflammation.

Error processing SSI file